What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
For addicts, cravings override all normal rules of behavior. In interviews throughout Northern Kentucky, addicts and...
A new initiative announced by the President Barack Obama Friday will see renewed efforts to collect...
The CDC warned the 2014-15 flu season would be a bad one and new numbers from...
The American Academy of Pediatrics (AAP), which has the largest pediatric publishing program in the world,...
